Patients with type 2 diabetes taking semaglutide face more than double the risk of developing a rare but serious eye condition that can cause permanent vision loss, according to the first comprehensive meta-analysis of observational studies. The finding adds to mounting evidence about potential ocular risks associated with the widely prescribed diabetes medication.
Semaglutide shows consistent NAION risk across study populations
Hazard ratios for nonarteritic anterior ischemic optic neuropathy, by comparison group
Source: Chrzanowski et al., PLOS Medicine 2025 | Georgian Medical Journal News
Meta-analysis reveals consistent elevated risk
The systematic review and meta-analysis, published in PLOS Medicine, examined five observational studies comparing diabetes patients treated with semaglutide to those receiving other glucose-lowering therapies. Led by Dr Jędrzej Chrzanowski and colleagues from multiple Polish medical institutions, the analysis found semaglutide use associated with a hazard ratio of 2.17 for developing nonarteritic anterior ischemic optic neuropathy (NAION).
NAION represents the most common cause of acute optic nerve damage in patients over 50, typically resulting in sudden, painless vision loss that is often irreversible. The condition occurs when blood flow to the optic nerve becomes compromised, leading to tissue damage and visual field defects.
The research team also examined semaglutide’s risk profile against non-GLP-1 receptor agonist therapies specifically, finding a similarly elevated hazard ratio of 2.13. This suggests the ocular risk pattern may be specific to semaglutide rather than the broader drug class.
Regulatory implications amid widespread use
The findings carry particular significance given semaglutide’s extensive global adoption for type 2 diabetes management and, increasingly, for weight loss under different brand formulations. The US Food and Drug Administration has already updated semaglutide labeling to include NAION as a potential adverse event following earlier case reports.
Dr Chrzanowski’s team employed rigorous methodology, searching PubMed, Scopus, and Web of Science databases from January 2023 to November 2025. Risk of bias was assessed using the Newcastle-Ottawa Scale and ROBINS-I tools, while evidence certainty was graded according to GRADE framework standards.
The analysis also included sensitivity testing with seven additional studies and leave-one-out analysis to assess potential publication bias. Across all analytical approaches, the elevated risk signal remained consistent, strengthening confidence in the primary findings.
Clinical monitoring recommendations emerge
While NAION remains a relatively rare condition even among high-risk populations, the doubling of risk represents a clinically meaningful increase that warrants consideration in treatment decisions. The absolute risk increase, while not quantified in this meta-analysis, must be weighed against semaglutide’s well-established benefits for glycemic control and cardiovascular outcomes in type 2 diabetes patients.
The research builds on earlier case reports that first raised concerns about potential semaglutide-NAION associations. However, this represents the first systematic attempt to quantify the risk using pooled observational data, providing more robust evidence for clinical decision-making.
Healthcare providers may need to consider enhanced ophthalmologic screening for patients initiating semaglutide therapy, particularly those with existing cardiovascular risk factors or other predisposing conditions for optic nerve ischemia. The patient safety implications extend beyond diabetes care to include coordination with ophthalmology specialists.
Semaglutide use was associated with a significantly increased hazard of NAION with a pooled hazard ratio of 2.17 (95% CI 1.73-2.74, p < 0.001)
— Dr Jędrzej Chrzanowski, Medical University of Lodz (PLOS Medicine, 2025)
Key takeaways
- Semaglutide users face 2.17 times higher risk of vision-threatening NAION compared to other diabetes treatments
- Risk elevation remains consistent across different comparison groups and analytical approaches
- Findings support need for enhanced ophthalmologic monitoring in semaglutide-treated patients
- Absolute risk remains low, but clinical significance warrants treatment decision consideration
Frequently asked questions
What is nonarteritic anterior ischemic optic neuropathy?
NAION is the most common cause of acute optic nerve damage in adults over 50, resulting from reduced blood flow to the optic nerve. It typically causes sudden, painless vision loss that is often permanent and irreversible.
Should patients stop taking semaglutide based on these findings?
Patients should not discontinue semaglutide without consulting their healthcare provider. The absolute risk remains low, and semaglutide provides significant benefits for diabetes management and cardiovascular health that must be weighed against potential risks.
What screening should semaglutide users consider?
While specific guidelines are still developing, patients starting semaglutide may benefit from baseline ophthalmologic evaluation and should promptly report any sudden vision changes to their healthcare providers.
The research underscores the importance of continued post-marketing surveillance for medications with rapidly expanding usage patterns. As semaglutide prescribing continues to grow globally, both for diabetes management and weight loss, comprehensive safety monitoring becomes increasingly critical for identifying and quantifying rare but serious adverse events that may not emerge in initial clinical trials.
Was this article helpful?
Related Coverage
